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Abstract
Triazole resistant A. fumigatus has been documented in many parts of the world. In the Netherlands, inci-
dence is now above 10% and results in the need for long-term parenteral therapy with liposomal ampho-
tericin B (LAmB). The long terminal half-life of LAmB suggests that intermittent dosing could be effective,
making the application of outpatient antifungal therapy (OPAT) possible. Here, we report our experience with
the use of OPAT for Invasive Fungal Infections (IFI). All adult patients treated with LAmB with a 2 or 3 times
weekly administration via the outpatient departments in four academic tertiary care centers in the Nether-
lands and Belgium since January 2010 were included in our analysis. Patient characteristics were collected,
as well as information about diagnostics, therapy dose and duration, toxicity, treatment history and outcome
of the IFI. In total, 18 patients were included. The most frequently used regimen (67%) was 5 mg/kg 3 times
weekly. A partial response to the daily treatment prior to discharge was confirmed by CT-scan in 17 (94%) of
patients. A favorable outcome was achieved in 13 (72%) patients. Decrease in renal function occurred in 10
(56%) cases but was reversible in all and was treatment limiting in one patient only. The 100-day mortality
and 1-year mortality after initiation of OPAT were 0% and 6%, respectively. In a selected population, and after
confirmation of initial response to treatment, our data support the use of OPAT with LAmB for treatment of
IFI in an intermittent dosing regimen.
Key words: Invasive fungal infection, liposomal amphotericin B, outpatient parenteral antibiotic treatment, triazole resistance,
antifungal stewardship.
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Background
Invasive fungal infections (IFI) are often life-threatening and oc-
cur predominantly in immunocompromised patients. After sur-
viving the initial phase of infection, prolonged treatment with
an antifungal agent is often necessary to ensure complete res-
olution.1,2 Unfortunately, the different antifungal drugs in the
current medical armamentarium all have shortcomings when
used for a prolonged period of time.3 For invasive aspergillo-
sis (IA) voriconazole became the first-choice treatment after an
improved survival was documented over conventional ampho-
tericin B (cAmB). Furthermore, voriconazole has a favorable ad-
verse event profile compared to conventional formulations of
amphotericin B and it is rarely associated with renal toxicity.4,5
Nevertheless, no direct comparison between voriconazole and
the more well-tolerated liposomal amphotericin B (LAmB) has
been made. In recent years, increasing rates of triazole resistant
Aspergillus fumigatus in particular in Europe but also in other
continents have become a major concern.6–10 This has led to
a renewed incentive to reconsider therapeutic strategies using
LAmB.11,12 For many IFI caused by non-Aspergillus fungi, for
example,Mucorales spp., LAmB already is the preferred first-line
treatment.13,14 Therefore, treatment with LAmB is increasingly
indicated and sometimes even the last resort in the management
of invasive fungal disease.
LAmB is solely administered in an intravenous formulation.
Both safety concerns and logistical reasons prevent dismissal
from the hospital during intravenous treatment; however, often
the treatment duration is long and exceeds the period of neces-
sity of hospitalization for clinical reasons.1,2 The practical lim-
itations of daily intravenous treatment are evident. Reduction
of duration of hospital stay would be favorable when consider-
ing both patient quality of life as well as economic costs. Fur-
thermore, continued daily intravenous administration will lead
to high cumulative dosages, associated with a higher rate of ad-
verse events. As an alternative, we have started to apply outpa-
tient antifungal therapy (OPAT) with LAmB. OPAT has been
implemented successfully in the past with various antibiotics.
In bacterial infections, increasing antimicrobial resistance rates
have made prolonged intravenous treatment with reserve antibi-
otics necessary. For example, the increasing rate of methicillin-
resistant Staphylococcus aureus has been an important reason
to apply prolonged OPAT with vancomycin.15–17 With LAmB,
outpatient use has recently been implemented in a prophylactic
setting.18
Two recent reviews of the pharmacokinetic properties of
LAmB strengthen the hypothesis that LAmB can effectively be
applied as OPAT.19,20 LAmB has a relatively short elimination
half-life of 7 hours shortly after initiation of therapy, which in-
creases to over 100 hours after prolonged use. This phenomenon
is attributed to accumulation in tissues and slow redistribu-
tion.21,22 When these pharmacokinetic properties of LAmB are
taken into account,23–25 it can be expected that a therapeutic
concentration can be attained in a less frequent dosing scheme.
Moreover, it may be possible to (partially) avoid nephrotoxic-
ity if the total dose of LAmB is spread over multiple days.25,26
Nephrotoxicity, however, remains an important caveat in the ap-
plication of OPATwith LAmB, as mentioned in pharmacological
review papers and in previous experimental experience.19,20,22,27
For those in need of prolonged antifungal treatment, step-
down therapy to intermittent dosing in the context of outpatient
treatment could offer similar efficacy with the potential of im-
proved safety. An intermittent dosing strategy is occasionally ap-
plied in several hospitals in the Netherlands and Belgium. In this
study, we are introducing the concept of treatment of IFI with
intermittent LAmB dosing as OPAT.
Methods
Study setting and patient population
A multicenter retrospective cohort study was conducted within
the Netherlands and Belgium. Hospitals that participate in the
Dutch-Belgian Mycoses study group (DB-MSG),28 a consortium
committed to the clinical research of IFI, were sent an inquiry
about their experience in the application of OPAT with LAmB
in the past 10 years. Of the 11 medical centers that participate in
the DB-MSG, four responded that they had applied OPAT with
LAmB in recent years. OPAT was applied at the home of the
patient or within the hospital outpatient department. All adult
patients treated with LAmB with a less frequently than daily ad-
ministration via the outpatient departments of Leiden University
Medical Center, Erasmus MC Rotterdam, Radboud University
Medical Center Nijmegen, and the University Hospitals Leuven
since January 2012 were included. These centers are all tertiary
care university hospitals and engaged in extensive solid organ
and hematopoietic stem cell transplantation programs.
Study protocols and definitions
No uniform protocols for the start of intermittent therapy with
LAmB were present. Typically for Aspergillus disease, a 3 mg/kg
dose was started. For Mucor species a typical dose was between
5 and 10 mg/kg. The choice to start treating with intermittent
therapy with LAmB was made according to the clinical judg-
ment of the treating physician usually based on imaging and clin-
ical course. Patients that were started on OPAT with LAmB were
closely monitored for the occurrence of nephrotoxicity, and most
patients received the drugs in the outpatient department of the
hospital. In the first month, all patients had at least a weekly
monitoring of electrolyte and kidney function. In the subsequent
weeks, monitoring occurred at least once every 2 weeks.
Nephrotoxicity was defined as a >1.5 times increase of
baseline serum creatinine levels resulting in an eGFR of
<40 ml/min/1.73 m2 during treatment or as electrolyte disor-
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cessation of treatment with LAmB at the discretion of the treat-
ing physician. Resolution of IFI was defined as clinically ob-
served absence of symptoms that are likely to be caused by IFI in
combination with findings concordant with resolution of IFI on
high-resolution CT-scan and the absence of the need to restart
antifungal therapy within 6 months.
Data collection
At the participating sites, lists of patients that received LAmB
as an outpatient were provided by the hospital pharmacy. Based
on these lists, the electronic medical records were examined to
ensure eligibility for inclusion in our study. The only inclusion
criterion was at least 2 weeks of intermittent treatment outside
of the hospital with LAmB for an invasive fungal infection meet-
ing the diagnostic criteria of the revised (2008) EORTC/MSG
definitions for invasive fungal disease.29
After retrieval of all relevant information, the data of all par-
ticipants were pseudonymized. Patient characteristics including
age, diagnosis of immunocompromising disease, diagnosis of IFI,
comorbidity, and immune status were collected, as well as infor-
mation about performed diagnostics, dosage of therapy, duration
of therapy, treatment history, switch of antifungal therapy, renal
function, and outcome of the IFI. The latter three variables were
considered the primary study outcomes to assess the safety and
efficacy of this strategy. IFI were classified according to the 2008
revised European Organisation for Research and Treatment of
Cancer – Mycoses Study Group criteria for the classification of
IFI.29
Analyses
Descriptive statistics of clinical variables of patients were calcu-
lated using the complete data set. Kaplan-Meier curves of sur-
vival during OPAT with LAmB were constructed. The analyses
were performed using STATA v. 16 (Statacorp, College Station,
TX, USA).
Ethics
The study was reviewed by the institutional review board of
the LUMC Leiden in the Netherlands, which confirmed that
the study did not fall under the Dutch law on research on hu-
man subjects. The institutional review board from UZ/KU Leu-
ven in Belgium approved the study. Data were processed after
pseudonymization by the local investigators and in accordance
with Personal Data Protection Acts of the respective countries.
Results
Between January 1st 2010 and September 1st 2018, a total of
18 adult patients received LAmB as an outpatient in a dosing
frequency of 2 or 3 times a week. Triazole resistance, demon-
strated by either polymerase chain reaction (PCR) or culture, has
been the most common reason (in 10 cases) to choose treatment
with LAmB instead of voriconazole in the patients with inva-
sive aspergillosis. Of all patients, nine (50%) were male, and the
median age was 60 years. Fourteen patients (78%) had a hema-
tological malignancy as underlying predisposing disease. Other
underlying diseases were chronic obstructive pulmonary disease
(COPD), sickle cell disease, and chronic granulomatous disease
(CGD). Suspected causative agents of IFI were Aspergillus spp.
(12 patients),Mucorales spp. (three patients),Fusarium spp. (two
patients), and a combination of bothAspergillus andMucor (one
patient). Table 1 summarizes the descriptive characteristics of
the study cohort. A response to treatment prior to discharge and
start of OPAT with LAmB was confirmed by CT scan in 17 pa-
tients. For the remaining patient, clinical improvement had been
the reason to proceed with OPAT. Patients switched from daily
treatment as an inpatient to intermittent OPAT with LAmB af-
ter a median of 56 days (range 14–193 days). Median dosage
of liposomal amphotericin B was 3 mg/kg, administered 3 times
eachweek. Some patients switched drug dosage and/or frequency
as detailed in the legend. None of the patients received com-
bination therapy. Resolution of infection was finally achieved
in 13 patients. The remaining patients were readmitted to the
hospital, switched to another antifungal, died, or were lost to
follow-up.
Nephrotoxicity during OPAT occurred in 10 cases, of which
in only one case treatment needed to be switched to another
antifungal agent (posaconazole, after establishing intermediate
sensitivity).
All patients in our data set had normalized renal functions
after decreasing of dosage or cessation of LAmB therapy. Severe
hypokalaemia (<2.5 mmol/l) was not observed during treatment
with LAmB in an intermittent scheme.Oral substitution of potas-
sium had been applied in two cases. Potassium levels raised to
normal levels during treatment in one of these patients and soon
after the end of intermittent treatment in the other patient.
For the remaining cases, the treating physician opted for
a dose reduction (four cases) or, after establishing a sufficient
treatment response, for the cessation of antifungal therapy (five
cases). The 100-day mortality and 1-year mortality were 0 and
1 out of 18 patients, respectively. All-cause mortality until the
end of follow-up was 39% but was related to the underlying
immunocompromising disease. In all cases treated for invasive
aspergillosis, the reason to treat with LAmB was triazole re-
sistance (demonstrated in 10 patients, presumed in three pa-
tients). Readmission to the hospital was necessary due to fac-
tors related to the infection (three patients) or to LAmB-related
nephrotoxicity (one patient). Figure 1 shows the survival rates
of all patients in a Kaplan Meier analysis since start of OPAT.
Figure 2 shows the time until resolution of infection. Figure 3









y/article/58/7/874/5713420 by guest on 15 February 2021
van de Peppel et al. 877
Table 1. Patient characteristics.
Total number of patients 18
Patient characteristics
Sex, male (%) 9 (50)
Age, median (range) 60 (18–78)





Aplastic anemia 1 (6)
CGD 1 (6)
Sickle cell disease 1 (6)
Prior allogeneic HSCT for any underlying disease 8 (44)





Reason to treat invasive aspergillosis with LAmB
Number of patients (% of patients with IA)
Triazole resistance identified with culture or PCR 10 (77)
Resistance presumed because IA occurred despite adequate prophylaxis with a triazole 2 (15)
Resistance presumed because IA showed progression despite adequate treatment with a triazole 1 (8)
Treatment
Dosage in mg/kg and frequency in times/week,† number of patients treated with the regimen at any point
2 mg/kg 3 times/week 1
3 mg/kg 2 times/week 1
3 mg/kg 3 times/week 12
5 mg/kg 3 times/week 2
6 mg/kg 3 times/week 5
10 mg/kg 2 times/week 2
Response to treatment confirmed by CT before start of intermittent therapy, number of patients (%) 17 (94)
Number of days between date of diagnosis and start of intermittent therapy, median number of days (range) 56 (14–193)
Nephrotoxicityˆ, number of patients (%)
Occurrence of nephrotoxicity at some point during intermittent LAmB treatment 10 (56)
Of which
– resulting in switch to other antifungal agent 1 (10)
– resulting in cessation of antifungal treatment (because of concurrent sufficient clinical and radiological response to treatment) 4 (40)
– resulting in dose or frequency reduction∼ 5 (50)
Outcome N = 18
Median number of days of follow-up, median (range) 741 (145–2543)
All-cause mortality at end of follow-up, number of patients (%) 7 (39)
100-day mortality after start of OPAT, number of patients (%) 0 (0)
1-year mortality after start of OPAT number of patients (%) 1 (6)
Resolution of infection,‡ number of patients (%) 13 (72)
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CGD, chronic granulomatous disease; CLL, chronic lymphatic leukemia; COPD, chronic obstructive pulmonary
disease; CT, computed tomography; HSCT, hematopoietic stem cell transplantation; IA, invasive aspergillosis; LAmB, liposomal amphotericin B; MDS-RAEB2, myelodysplastic
syndrome with refractory anemia with excess blasts-2; PCR, polymerase chain reaction.
*Numbers add up to more than 100% due to one patient suffering from an infection caused by both Mucor and Aspergillus.
ˆNephrotoxicity defined as either serious electrolyte disturbances necessitating treatment cessation at the discretion of the treating clinician or at least 50% increase of creatinine
levels resulting in a eGFR of <40 ml/min.
†Numbers add up to more than 100% because of 5 patients with dose alterations during the study period.
∼Dose reductions were as follows: two patients treated with 6 mg/kg 3 times weekly and one patient treated with 5 mg/kg 3 times/week were switched to 3 mg/kg 3 times
weekly. Of two patients treated with 3 mg/kg 3 times/week, one was switched to 3 mg/kg 2 times/week and one patient was switched to 2 mg/kg 3 times/week. Kidney function
normalized in all five patients.
‡Resolution of infection defined as clinically observed absence of symptoms that are likely to be caused by invasive fungal infection in combination with clinically irrelevant or
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Figure 1.Overall survival from start of intermittent treatment. Censored cases
were lost to follow-up. LAmB, liposomal amphotericin B; OPAT, outpatient an-
tifungal therapy.
Figure 2. Time to resolution of IFI after start of intermittent therapy. Censored
cases stopped intermittent treatment before resolution of infection. Resolu-
tion of IFI was defined as clinically observed absence of symptoms that are
likely to be caused by IFI in combination with findings concordant with reso-
lution of IFI on high-resolution CT scan. IFI, invasive fungal infection; LAmB,
liposomal amphotericin B; OPAT, outpatient antifungal therapy.
Discussion
This study shows that the use of OPAT with LAmB in a 2 or
3 times weekly dosing scheme results in high rates of therapy re-
sponse in a selected patient population and after confirmation
of an initial response to daily IV therapy with LAmB. However,
safety issues did arise, resulting in mostly reversible nephrotox-
icity and in some cases infection or therapy-related readmission
to the hospital.
The majority of patients in this study needed prolonged use of
LAmB for the treatment of triazole resistant A. fumigatus infec-
tions. After the first reports of voriconazole-resistant A. fumiga-
tus appeared in 2009 from the Netherlands,30 triazole resistance
has now extensively been reported in many regions all over the
world.7,11 Although the prevalence is low in some regions, the
rates have been steadily increasing in others.7,31 The high rates
Figure 3. Occurrence of nephrotoxicity from start of intermittent treatment.
Censored cases stopped intermittent treatment before nephrotoxicity oc-
curred. Nephrotoxicity was defined as a >1.5 times increase of baseline serum
creatinine levels resulting in an eGFR of < 40ml/min/1.73 m2 during treatment
or as electrolyte disorders suspected to be the result of renal damage and re-
quiring cessation of treatment with LAmB at the discretion of the treating clin-
ician. LAmB, liposomal amphotericin B; OPAT, outpatient antifungal therapy.
of triazole resistance also impact decision making in patients for
whom susceptibility testing is not possible. In many cases, the
clinician may fear presence of resistance in case of worsening of
clinical or diagnostic parameters after treatment with a triazole
even with negative or absent resistance tests. Because of diffi-
culty in establishing triazole-resistance or sensitivity, the clinical
suspicion of resistance is becoming an important reason to ab-
stain from further treatment with triazoles and opting for LAmB
instead. Fortunately, more possibilities to detect resistance have
become available. The impact of resistance testing of invasive
aspergillosis using PCR is expected to more effectively guide the
clinician in the optimal choice of therapy32 and is being evalu-
ated in a prospective multicentre study in the Netherlands and
Belgium (NCT03121235).
Renal toxicity
Since the introduction of (conventional) amphotericin B as treat-
ment of fungal infections, nephrotoxicity has been a major con-
cern. Nevertheless, nephrotoxicity has significantly decreased af-
ter the introduction of the liposomal formulation of ampho-
tericin B.33–36 In particular, patients that need prolonged ther-
apy and are exposed to high doses over a prolonged period of
time are vulnerable for the development of renal adverse events.
A decrease in dosage could also be beneficial in mitigating the
drug-related renal toxicity. However, nephrotoxicity occurring
at the end of the anticipated therapy period has been a reason to
stop antifungal treatment prematurely and instead evaluate the
natural course of the disease. Importantly, the associated nephro-
toxicity was reversible in the majority of cases after cessation
of therapy or dose alteration. The occurrence and time course
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with daily dosing.37–39 Additionally, some experience in the as-
sessment of the safety of the use of LAmB in an outpatient setting
is previously described by Malani et al. in 2005.27 The authors
of this study also found high rates of nephrotoxicity; the results
are nonetheless not directly comparable due to their inclusion
of application of non-lipid formulations of amphotericin B. The
mentioned literature reports generally lower rates of reversibil-
ity of nephrotoxicity and shorter duration until occurrence of
nephrotoxicity. However, a recent study also reports a high rate
of reversibility of nephrotoxicity after use of LAmB.40 Possibly,
our data supports the theory that nephrotoxicity occurs later and
has a higher probability to be reversible when applying LAmB in
an intermittent dosing schedule.
Application of OPAT strategies are slowly expanding within
the field of infectious diseases and are being implemented in reg-
ular practice. Similar to LAmB, intravenous vancomycin ther-
apy is also associated with renal toxicity but has nonetheless
been successfully implemented in an OPAT program for many
years now.16,17 Despite early reluctance, the expected logistic and
toxicity-related disadvantages41,42 are outweighed by the advan-
tages of a decrease in hospital stay with similar therapeutic effec-
tiveness thanks to the implementation of monitoring of toxicity
and therapeutic drug monitoring.15,17,43
Study strengths and limitations
Despite a nation-wide inquiry, only a small subset of adult pa-
tients treated for IFI have been identified. The means by which
these patients have been selected to undergo OPAT is inherently
biased, that is, the decision of the clinician to apply this thera-
peutic strategy has been dependent on many factors, both known
and unknown. Since no guideline refers to or advises OPAT with
LAmB, and due to lack of supportive literature, physicians may
only have elected this approach in specific situations. Addition-
ally, lack of existing intra- or extramural infrastructure to apply
OPAT could be a limiting factor. Due to this selection, presum-
ably patients with a relatively favorable prognosis with regard
to the IFI were included in our study. Also, the heterogeneity
of both the patient population and the different dosings that
have been used make it difficult to draw any hard conclusions
about efficacy and tolerability. As it is impossible to adjust for
all of these factors, the results of our study cannot be directly
compared with other cohorts of patients with IFI. However, the
baseline variables that have been presented summarize the most
important characteristics, possibly contributing to identifying
potentially eligible patients for this treatment strategy. Only pa-
tients with an initial response to therapy with LAmB showing no
or only mild prior adverse events related to LAmB use were sub-
jected to this strategy. Hence, the involved physicians balanced
the risks of inadequate treatment of invasive fungal disease
against the advantages of treatment in the outpatient setting.
For future adaptation of this strategy, it is important for the
clinician to weigh these factors before deciding on applying
OPAT with LAmB.
After documentation of an initial treatment response and in
a selected patient group, intermittent therapy with LAmB in the
outpatient setting appeared to be a valuable treatment option for
IFI. Frequent monitoring of renal function and potassium levels,
for example once every week, is strongly recommended for early
recognition of nephrotoxicity, as it can also occur during pro-
longed OPAT. This treatment strategy is expected to provide ad-
vantages in costs, decrease of hospital-associated infections and
patient’s quality of life. Further research will be necessary to ex-
pand upon the possibilities that this treatment strategy offers.
The identification of eligible patient populations that wouldmost
benefit from this strategy as well as further study of the toxicity
concerns in this setting are warranted.
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